NanoCor's People
 


NanoCor's Team

NanoCor’s team is highly experienced in virology (AAV in particular), in the cardiovascular field and in the development of gene therapy based therapeutics.  Dr. Richard Jude Samulski, the developer of the BNP™ technology, has almost 30 years of experience in rAAV and is the Director of the Gene Therapy Center at the University of North Carolina – Chapel Hill.  Dr. Evangelia Kranias, the developer of the I-1 technology, is well known for her work in phospholambam and the biology of heart failure, and is the Distinguished Professor and Director of Cardiovascular Biology at the University of Cincinnati. Dr. Roger Hajjar is a leader in gene therapy techniques and model testing for cardiovascular diseases.

Management Team

Sheila A. Mikhail, J.D., M.B.A.
Founder, Chief Executive Officer

Board of Directors

Sheila A. Mikhail, J.D., M.B.A.
Founder, Chief Executive Officer

Jude Samulski, Ph.D.

Scientific Founder, Collaborator

Gerald L. Klein, M.D.
Board Member

Founders

Sheila A. Mikhail, J.D., M.B.A.
Founder, Chief Executive Officer

Gabor M. Rubanyi, M.D., Ph.D.
Founder

Scientific Advisory Board

Jude Samulski, Ph.D.

Scientific Founder, Collaborator

Evangelia Kranias, Ph.D.
Scientific Founder, Collaborator

Roger Hajjar, MD, Ph.D.
Scientific Founder, Collaborator

William Abraham, M.D.
Director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center and a professor of Internal Medicine.

Thomas DiSalvo, M.D.
Chief Medical Director of the Vanderbilt Heart and Vascular Institute.

Joshua Hare, M.D.
Chief of the Division of Cardiology and director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine.

David Kass, M.D.
Professor of Medicine and Biomedical Engineering at Johns Hopkins University and a cardiology staff member at Johns Hopkins Hospital.

Leslie Miller, M.D.
Chief of the Integrated Divisions of Cardiology at the Georgetown University School of Medicine, Georgetown University Hospital and Washington Hospital Center.

Sir Magdi Yacoub, M.D.
British Heart Foundation Professor of Cardiothoracic Surgery at Imperial College of London and Founder and Director of Research at The Magdi Yacoub Institute, Heart Science Centre Harefield. Sir Yacoub has performed more transplants than any other surgeon in the world and has personally tended to Queen Elizabeth II.

Collaborators

UNC Chapel Hill
Massachusetts General Hospital/Harvard
University of Cincinnati
Mount Sinai Medical Center

   
    NanoCor's Team
 


Management Team   Management Team

Board of Directors   Board of Directors

Founders   Founders

Advisory Board   Advisory Board

Collaborators   Collaborators
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

    Contact Us
 


Address    870 Martin Luther King Jr. Blvd.
    Chapel Hill, NC 27514
      
Phone    (919) 942-0252

email   smikhail@nanocorthx.com
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

 

NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a non-invasive treatment for these patients and advance the current standard of care.

        Copyright © 2009 NanoCor Therapeutics. All Rights Reserved.                    |                  Chapel Hill, North Carolina 27514                   |                   Disclaimer